Aehr Test Systems
AEHR
$80.24
+4.77%
Aehr Test Systems designs, manufactures, and sells advanced test and burn-in systems for logic, optical, and memory integrated circuits, primarily serving the semiconductor manufacturing industry. The company is a niche player in the semiconductor test equipment market, with a focus on high-reliability applications such as automotive and mobility ICs, and has recently pivoted to capitalize on the AI infrastructure build-out. The current investor narrative centers on Aehr's strategic shift from electric vehicle (EV) applications to AI processor testing, which has driven record bookings and a surge in stock price, with revenue expected to triple next year. The company's role in the booming AI data center spending, particularly for power components and specialized testing equipment, has made it a high-growth, high-volatility small-cap story.…
AEHR
Aehr Test Systems
$80.24
Related headlines
Investment Opinion: Should I buy AEHR Today?
Rating: Buy. Aehr Test Systems is a high-growth, high-risk opportunity with a unanimous Strong Buy analyst consensus and an average target price of $130, implying 60.9% upside. The thesis is anchored on the company's successful pivot to AI processor testing, which has driven record bookings and a 40.2% YoY revenue surge in Q4 FY2026, with revenue expected to triple next year.
Sign up to view all
AEHR 12-Month Price Forecast
The AI assessment is bullish but with medium confidence, given the strong growth trajectory and analyst support, but tempered by extreme valuation and volatility. The key factor is whether Aehr can deliver on the projected revenue tripling; if it does, the stock is likely undervalued, but any shortfall could lead to a sharp correction. I would upgrade to high confidence if the company reports another quarter of 40%+ YoY growth and raises guidance, and downgrade to bearish if revenue growth decelerates below 20% or if major orders are cancelled.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Aehr Test Systems's 12-month outlook, with a consensus price target around $130.00 and implied upside of +62.0% versus the current price.
Average Target
$130.00
0 analysts
Implied Upside
+62.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$110 - $175
Analyst target range
Aehr has coverage from 4 analysts, with a consensus recommendation of 'Strong Buy' (mean rating 1.0). The average target price is $130.00, implying approximately +60.9% upside from the current price of $80.81. The target range is $110.00 to $175.00, with the low target still representing +36.1% upside, indicating a bullish outlook across the board. The high target of $175.00 suggests potential for further multiple expansion or stronger-than-expected growth, while the low target may reflect risks such as margin compression or competitive pressures. Recent ratings actions include an upgrade from William Blair (Market Perform to Outperform) in March 2026, and a downgrade from Craig-Hallum (Buy to Hold) in March 2024, but the current consensus is strongly positive.
Bulls vs Bears: AEHR Investment Factors
Aehr Test Systems presents a high-risk, high-reward opportunity driven by its successful pivot to AI processor testing, which has generated record bookings and a 40.2% YoY revenue surge. The bull case is supported by a unanimous Strong Buy analyst consensus, a 60.9% average target upside, and expectations of revenue tripling next year. However, the bear case is equally compelling, with a trailing P/S of 56.6x, negative earnings, and extreme volatility (beta 3.09) that has already produced a -44.5% drawdown. The single most important tension is whether the massive revenue growth implied by the forward P/S of 10.3x will materialize; if it does, the stock is undervalued, but if it falters, the valuation could compress dramatically. Currently, the bull evidence is stronger given the concrete bookings and analyst confidence, but the risk of a sharp correction remains high.
Bullish
- AI pivot driving record bookings: Aehr's strategic shift from EV to AI processor testing has generated record bookings, including a $37.2 million order in Q4 FY2026, fueling a 40.2% YoY revenue surge to $19.75 million. This validates the company's critical role in the AI infrastructure build-out, with revenue expected to triple next year.
- Strong analyst consensus and upside: All 4 analysts rate AEHR a Strong Buy (mean 1.0), with an average target of $130.00, implying 60.9% upside from the current price of $80.81. Even the low target of $110.00 offers 36.1% upside, reflecting broad confidence in the growth trajectory.
- Massive forward revenue growth expected: Analysts project FY2027 revenue of $275.55 million, a 3.5x increase from the current annualized run-rate of ~$79 million. This growth is anchored by AI-related orders and the expansion of test capacity for power components in data centers.
- Improving profitability in latest quarter: Q4 FY2026 marked a return to profitability with EPS of $0.05 and net income of $1.39 million, reversing losses from the prior three quarters. Gross margin expanded to 40.6% from 32.7% in Q3, indicating operating leverage as revenue scales.
Bearish
- Extreme valuation with negative earnings: The trailing P/S ratio of 56.6x is astronomically high, and the company has negative trailing EPS (-$0.0025) and negative operating margin (-28.3%). Even the forward P/S of 10.3x assumes flawless execution of the revenue tripling, leaving no room for disappointment.
- High volatility and beta risk: With a beta of 3.09, AEHR is highly sensitive to market swings, and its 1-year price change of +198.7% versus the S&P 500's +18.6% shows extreme momentum-driven moves. The stock has already experienced a -44.5% max drawdown, highlighting the risk of sharp corrections.
- Revenue concentration and customer risk: Aehr's revenue is heavily dependent on a few large customers, particularly in the AI and automotive sectors. The recent pivot to AI introduces execution risk, as any delay or cancellation of major orders (like the $37.2 million one) could severely impact financials.
- Negative free cash flow and profitability concerns: Trailing twelve-month free cash flow is -$5.38 million, and the company has posted losses in 7 of the last 8 quarters. The path to sustained profitability is uncertain, especially if revenue growth slows or margins fail to expand as expected.
AEHR Technical Analysis
Aehr Test Systems is in a strong long-term uptrend, with a 1-year price change of +198.7%, significantly outperforming the S&P 500's +18.6% over the same period. The current price of $80.81 sits at 48.5% of the 52-week range (low $18.70, high $147.40), indicating a significant pullback from the highs but still well above the lows. This positioning suggests the stock is in a corrective phase after a massive rally, with potential support near the 52-week low and resistance at the high.
Beta
3.09
3.09x market volatility
Max Drawdown
-47.4%
Largest decline past year
52-Week Range
$19-$147
Price range past year
Annual Return
+222.5%
Cumulative gain past year
| Period | AEHR Return | S&P 500 |
|---|---|---|
| 1m | -12.5% | +1.0% |
| 3m | -31.2% | +1.1% |
| 6m | +125.3% | +13.8% |
| 1y | +222.5% | +19.5% |
| ytd | +262.1% | +12.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AEHR Fundamental Analysis
Aehr's revenue trajectory is volatile but showing signs of recovery. In the most recent quarter (Q4 FY2026, ended May 29, 2026), revenue was $19.75 million, up 40.2% year-over-year, a sharp acceleration from the previous quarter's $10.31 million (down 43.7% YoY). The multi-quarter trend shows a trough in Q2 FY2026 ($9.88 million) followed by sequential growth, indicating a potential turnaround. Revenue segments for the quarter included Systems ($6.76 million), Contactors ($2.61 million), and Services ($1.59 million), with Systems being the primary driver. The growth is attributed to AI-related orders, as highlighted in recent news, which could sustain momentum.
Quarterly Revenue
$19751000.0B
2026-05
Revenue YoY Growth
+40.2%
YoY Comparison
Gross Margin
40.6%
Latest Quarter
Free Cash Flow
$-5376000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AEHR Overvalued?
Given that Aehr's trailing twelve-month net income is negative (EPS of -$0.0025), the price-to-sales (PS) ratio is the primary valuation metric. The trailing PS ratio is 56.6x, while the forward PS ratio (based on estimated revenue of $275.55 million) is approximately 10.3x, implying the market expects a massive revenue increase. The gap between trailing and forward PS suggests high growth expectations, but the current valuation is extremely rich if growth does not materialize.
PE
-401.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 4x~168x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-232.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Aehr's financials reveal significant risks, including a negative trailing EPS of -$0.0025 and an operating margin of -28.3%, indicating ongoing losses. The company's free cash flow is negative at -$5.38 million TTM, and it has relied on external funding, though its low debt-to-equity of 0.045 provides some cushion. Revenue is highly volatile, with quarterly swings from $9.88 million to $19.75 million, and the recent growth is concentrated in a few large orders, creating concentration risk. If the AI-driven orders fail to repeat or are delayed, the company could face cash flow strain and potential dilution to fund operations.